EUVIMEDOpdag EUVIMED
Leserbrief

Successful first‐line treatment of hemophagocytic lymphohistiocytosis with ruxolitinib in a pediatric patient with trisomy 21

Katelyn N Swizer, Morgan Beebe, Miriam B Garcia iD

Pediatric Blood & Cancer · 2023

DOI: 10.1002/pbc.30241 ↗

At a glance

Leserbrief in Pediatric Blood & Cancer, 2023. Written by Katelyn N Swizer and 2 co-authors. Institution: Department of Pediatrics, University of Michigan C.S. Mott Children's Hospital, Ann Arbor, Michigan, USA. Major MEDLINE topics: Lymphohistiocytosis, Hemophagocytic, Down Syndrome. Cited 1 times so far (Crossref); 12 references.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Hemophagocytic lymphohistiocytosis (HLH) is an uncommon immunologic disorder associated with high rates of morbidity and mortality characterized by systemic inflammation and multiorgan dysfunction. The standard of care for primary treatment of HLH is chemotherapy (i.e. etoposide), but consideration of alternative therapies is warranted to support treatment goals for critically ill pediatric patients. We present the case of a 7-year-old male with trisomy 21, acute multiorgan failure secondary to infection, and subsequent HLH who was successfully treated with ruxolitinib. This represents the first use of ruxolitinib as a first-line agent for secondary HLH in a critically ill child with trisomy 21.

Subjects

MeSH terms (MEDLINE)

Lymphohistiocytosis, HemophagocyticDown SyndromeHumansChildNitrilesPyrimidinesPyrazoles

Substances

NitrilesPyrimidinesruxolitinibPyrazoles

Authors and institutions

  • Department of Pediatrics, University of Michigan C.S. Mott Children's Hospital, Ann Arbor, Michigan, USA.
  • Department of Pediatrics, Nationwide Children's Hospital, Columbus, Ohio, USA.
  • Department of Pediatrics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID profiles: Miriam B Garcia

Cite

APA

Swizer, K. N., Beebe, M., & Garcia, M. B. (2023). Successful first‐line treatment of hemophagocytic lymphohistiocytosis with ruxolitinib in a pediatric patient with trisomy 21. Pediatric Blood & Cancer. https://doi.org/10.1002/pbc.30241

Vancouver

Swizer KN, Beebe M, Garcia MB. Successful first‐line treatment of hemophagocytic lymphohistiocytosis with ruxolitinib in a pediatric patient with trisomy 21. Pediatric Blood & Cancer. 2023. doi:10.1002/pbc.30241

BibTeX
@article{Swizer2023,
  author = {Swizer, Katelyn N and Beebe, Morgan and Garcia, Miriam B},
  title = {Successful first‐line treatment of hemophagocytic lymphohistiocytosis with ruxolitinib in a pediatric patient with trisomy 21},
  journal = {Pediatric Blood & Cancer},
  year = {2023},
  doi = {10.1002/pbc.30241}
}
Start for free →